Journal of diabetes research

Tirzepatide and its research on fatty liver disease linked to metabolism problems

Updated

Abstract

Tirzepatide is associated with substantial weight loss and improved liver biomarkers in patients with metabolic dysfunction-associated steatohepatitis (MASH).

  • Scientific output on tirzepatide and MASH has rapidly increased since 2020.
  • Thematic clusters in the literature focus on metabolic regulation, hepatic inflammation, and fibrosis.
  • Tirzepatide shows improvements in liver biomarkers such as ALT, AST, K 18, and Pro C3.
  • The SYNERGY nonalcoholic steatohepatitis (NASH) trial reported high rates of MASH resolution without worsening fibrosis.
  • Network meta-analyses indicate tirzepatide is among the most effective therapies for metabolic liver disease.
  • Current guidelines recommend tirzepatide for MASLD patients with obesity, type 2 diabetes, or cardiometabolic risk.

Simplified

Full Text

Full text is available at the source.

Funding

Competing interests

The authors declare no conflicts of interest.
PubMed

What Lands in Your Inbox Each Week:

  • 📚7 fresh studies
  • 📝plain-language summaries
  • direct links to original studies
  • 🏅top journal indicators
  • 📅weekly delivery
  • 🧘‍♂️always free